Additionally, the 36-month beta value for TSVT is 1.87. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TSVT is 47.64M and currently, short sellers hold a 14.29% ratio of that float. The average trading volume of TSVT on April 25, 2024 was 1.45M shares.
TSVT) stock’s latest price update
The stock price of 2seventy bio Inc (NASDAQ: TSVT) has plunged by -7.78 when compared to previous closing price of 4.63, but the company has seen a -15.61% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-17 that The FDA’s recent nod to 2seventy bio’s (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
TSVT’s Market Performance
2seventy bio Inc (TSVT) has seen a -15.61% fall in stock performance for the week, with a -12.86% decline in the past month and a 38.19% surge in the past quarter. The volatility ratio for the week is 8.76%, and the volatility levels for the past 30 days are at 9.40% for TSVT. The simple moving average for the past 20 days is -15.95% for TSVT’s stock, with a -8.98% simple moving average for the past 200 days.
Analysts’ Opinion of TSVT
Many brokerage firms have already submitted their reports for TSVT stocks, with Leerink Partners repeating the rating for TSVT by listing it as a “Outperform.” The predicted price for TSVT in the upcoming period, according to Leerink Partners is $18 based on the research report published on January 31, 2024 of the current year 2024.
Leerink Partners gave a rating of “Market Perform” to TSVT, setting the target price at $6 in the report published on October 30th of the previous year.
TSVT Trading at -16.86% from the 50-Day Moving Average
After a stumble in the market that brought TSVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.35% of loss for the given period.
Volatility was left at 9.40%, however, over the last 30 days, the volatility rate increased by 8.76%, as shares sank -13.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.87% lower at present.
During the last 5 trading sessions, TSVT fell by -15.61%, which changed the moving average for the period of 200-days by -61.88% in comparison to the 20-day moving average, which settled at $5.05. In addition, 2seventy bio Inc saw 0.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSVT starting from Casdin Capital, LLC, who purchase 40,000 shares at the price of $5.10 back on Mar 26 ’24. After this action, Casdin Capital, LLC now owns 2,000,000 shares of 2seventy bio Inc, valued at $203,992 using the latest closing price.
Casdin Capital, LLC, the Director of 2seventy bio Inc, purchase 330,000 shares at $5.07 during a trade that took place back on Mar 25 ’24, which means that Casdin Capital, LLC is holding 1,960,000 shares at $1,673,991 based on the most recent closing price.
Stock Fundamentals for TSVT
Current profitability levels for the company are sitting at:
- -2.37 for the present operating margin
- 0.8 for the gross margin
The net margin for 2seventy bio Inc stands at -2.12. The total capital return value is set at -0.47. Equity return is now at value -76.91, with -35.61 for asset returns.
Based on 2seventy bio Inc (TSVT), the company’s capital structure generated 0.5 points at debt to capital in total, while cash flow to debt ratio is standing at -0.65. The debt to equity ratio resting at 1.01. The interest coverage ratio of the stock is 51.41.
Currently, EBITDA for the company is -206.42 million with net debt to EBITDA at -0.98. When we switch over and look at the enterprise to sales, we see a ratio of 3.99. The receivables turnover for the company is 7.49for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.98.
Conclusion
In conclusion, 2seventy bio Inc (TSVT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
